Heritage Trust’s AstraZeneca AZN Stock Holding History

Heritage Trust’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-92	Closed	-$6K	–	398
2017 Q3	$6K	Buy	+92	New	+$5.81K	﹤0.01%	303

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Heritage Trust's AZN Position: Q4 2017 in Review

Heritage Trust sold out of AstraZeneca (AZN) in Q4 2017, closing a stake of 92 shares — an estimated $6K sold.

Heritage Trust first reported a position in AZN in Q3 2017 and held it in 1 quarter. The position peaked at $6K in Q3 2017. 503 funds tracked by Wall St. Rank hold AZN as of Q4 2017.

Heritage Trust reported no remaining AstraZeneca position as of Q4 2017 after selling out during the quarter.
Heritage Trust sold 92 AstraZeneca shares in Q4 2017, an estimated $6K.
Heritage Trust first reported a position in AstraZeneca in Q3 2017 and held it in 1 quarter.
Heritage Trust's AstraZeneca position peaked at $6K in Q3 2017.
503 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2017.

Based on Heritage Trust's 13F filing for Q4 2017, filed 12 Feb 2018.